B. Braun Melsungen AG
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From B. Braun Melsungen AG
A regulatory system that cannot function as intended, even with an extra year for preparation, will become mandatory in the EU next week. German medtechs suggest a route forward.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.
BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December.
Market Brief: Global Orthobiologics Market Will Reach $2.3Bn By 2023 With Highest Growth In Cartilage Replacement
The global market for orthobiologics for musculoskeletal soft tissue replacement and regeneration is expected to reach $2.3bn by 2023, according to a new report by Informa's Meddevicetracker. This highly competitive market, which is led by Arthrex and other large and smaller players, continues to grow amid the rising prevalence of musculoskeletal soft tissue injuries and osteoarthritis. High prices of implants, the limited availability of donated tissue and limited reimbursement for synthetic scaffolds are limiting growth in this market.
- Medical Devices
- Group Purchasing
- Home Infusion
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Aesculap AG
- Aesculap Inc.
- Aesculap Implant Systems
- B. Braun Medical Inc.
- B. Braun Medical SAS
- B. Braun Miethke GmbH & Co. KG
- Central Admixture Pharmacy Services, Inc.
- Dextera Surgical, Inc.
- Lauer Membran Wassertechnik GmbH
- McGaw, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.